Effect of Body Mass Index– and Actual Weight–Based Neoadjuvant Chemotherapy Doses on Pathologic Complete Response in Operable Breast Cancer
R. Ganapathi Raman(University of Iowa), Alexandra Thomas(Cliniques Universitaires Saint-Luc), Jad El Masri(University of Iowa), Sarah L. Mott(University of Iowa), Mary C. Schroeder(University of Iowa), Sneha Phadke(University of Iowa Hospitals and Clinics)
Cited by 28
Related Papers
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial
|Cancer Cell|2021|330
Sarcopenia is an independent predictor of complications following pancreatectomy for adenocarcinoma
|Journal of Surgical Oncology|2014|274
Indications for and outcome of total abdominal hysterectomy for benign disease: a prospective cohort study
|BJOG An International Journal of Obstetrics & Gynaecology|1995|215
Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer
|The Journal of Urology|2019|190